This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): risperidone, Belivon, Rispen, R064766
Description: Risperdal is an atypical antipsychotic with a higher affinity for the serotonin 5-HT2 receptor relative to its affinity for the dopamine D-2 receptor. Though the exact mechanism is unclear it has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.
Atypical antipsychotics are able to produce an antipsychotic effect (through blockade of D-2 receptors in the ventral striatum) with fewer extrapyramidal motor function side effects (or EPSs, which are caused by blockade of D-2 receptors in the dorsal striatum).
RISPERDAL is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), a1 and a2 adrenergic, and H1 histaminergic receptors. RISPERDAL acts as an antagonist at other receptors,but with lower potency. RISPERDAL has low to moderateaffinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for thedopamine D1 and haloperidol-sensitive sigma site, and no affinity(when tested at concentrations >10-5 M) for cholinergicmuscarinic or ß1 and ß2 adrenergic receptors.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Organon and Johnson & Johnson
In March of 2005, Akzo Nobels human healthcare business, Organon, and Johnson & Johnsons Janssen-Cilag mutually agreed to end the co-promotion of Risperdal. The two companies who have collaborated on the product since 1993 terminated their arrangement in Europe, Argentina and Brazil and replaced it with a financial agreement. The new agreement has no material impact on Organons future royalty income. Upfront payments of EUR 125 million upon signing and EUR 25 million in January 2006 will be made to Organon.
Schering-Plough and Organon
In November 2007, Schering-Plough announced that it completed the acquisition of Organon BioSciences N.V. Schering-Plough acquired Organon BioSciences from Akzo Nobel N.V. for approximately euro 11 billion in cash.
Schering-Plough and Merck
In March 2009, Merck & Co and Schering-Plough announced that their Boards of...See full deal structure in Biomedtracker
Additional information available to subscribers only: